IBDIQ
Live / Allowed — Notice of allowance issued (as of 10 Jun 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 04 Jun 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98584115
- Mark type
- Stylized text
- Filed
- 04 Jun 2024
- Published for opposition
- 15 Apr 2025
- Attorney of record
- Karl M. Zielaznicki, Esq.
Goods and services
- Class 044 — Medical, beauty and agricultural services: Healthcare provider and medical professional support program providing disease awareness and disease management information and materials in the nature of providing a website featuring medical information to improve the understanding of healthcare providers and medical professionals about inflammatory bowel disease (IBD) and pharmaceutical treatment thereof
Owner
- Takeda Pharmaceuticals U.S.A., Inc., Cambridge, MA, US
- Takeda Pharmaceuticals U.S.A., Inc., Cambridge, MA, US
Prosecution history
- 17 Nov 2025 — TEAS STATEMENT OF USE RECEIVED
- 11 Nov 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 11 Nov 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 11 Nov 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 10 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 15 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Apr 2025 — PUBLISHED FOR OPPOSITION
- 09 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 17 Feb 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 17 Feb 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 17 Feb 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 20 Dec 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 20 Dec 2024 — NON-FINAL ACTION E-MAILED
- 20 Dec 2024 — NON-FINAL ACTION WRITTEN